Discrimination between rival dosing histories

被引:14
作者
Jonsson, EN
Wade, JR
Almqvist, G
Karlsson, MO
机构
[1] ASTRO DRACO AB,DEPT HUMAN PHARMACOL,LUND,SWEDEN
[2] UPPSALA UNIV,DEPT PHARM,UPPSALA,SWEDEN
[3] MED PROD AGCY,UPPSALA,SWEDEN
关键词
compliance; dosing history; NONMEM; population pharmacokinetic analysis;
D O I
10.1023/A:1012184808192
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. In population pharmacokinetic studies, the dosing history is sometimes recorded in more than one way. The purpose of this study was to develop and evaluate a procedure for discriminating between rival dosing histories, i.e., for each individual in a data set, identify the dosing history that is the most plausible. Methods. The procedure consists of four steps. In the first step we identify individuals whose dosing histories produce predictions that are consistent. in the second step these individuals are used to build a population pharmacokinetic model which is used, in step three, to select the dosing history for the individuals not identified in step one. In step four the population model is refined using the best available dosing histories for all individuals. The proposed procedure was evaluated using both simulations and a real data set, in which two dosing histories, based on patient diaries and electronic monitoring devices (MEMS) were available. Results. In the real data set, estimated variabilities were almost always lower when the selected dosing histories were used compared to when no selection procedure was used. The diary dosing histories were selected more often than the MEMS dosing histories. In the simulations, the parameter estimates obtained using the selection procedure were closer to the true parameter values compared to when only one of the dosing histories was used. Conclusions. The proposed procedure appears to be robust and should be beneficial in at least two respects: improved parameter estimation of population pharmacokinetic and PK/PD models and objective information by which dosage recording methodologies can be compared and patient dose recording behavior can be assessed.
引用
收藏
页码:984 / 991
页数:8
相关论文
共 13 条
[1]   SPARSE DATA-ANALYSIS [J].
AARONS, L .
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 1993, 18 (01) :97-100
[2]   THE APPLICATION OF POPULATION PHARMACOKINETIC ANALYSIS TO LARGE-SCALE CLINICAL EFFICACY TRIALS [J].
ANTAL, EJ ;
GRASELA, TH ;
SMITH, RB .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1991, 19 (03) :S37-S46
[3]   ABC OF MONITORING DRUG-THERAPY - PATIENT COMPLIANCE [J].
ARONSON, JK ;
HARDMAN, M .
BRITISH MEDICAL JOURNAL, 1992, 305 (6860) :1009-1011
[4]  
BOECKMANN AJ, 1992, NONMEM USERS GUIDES
[5]   PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].
COCKCROFT, DW ;
GAULT, MH .
NEPHRON, 1976, 16 (01) :31-41
[6]   Population pharmacokinetic modeling: The importance of informative graphics [J].
Ette, EI ;
Ludden, TM .
PHARMACEUTICAL RESEARCH, 1995, 12 (12) :1845-1855
[7]   Three new residual error models for population PK/PD analyses [J].
Karlsson, MO ;
Beal, SL ;
Sheiner, LB .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1995, 23 (06) :651-672
[8]   THE IMPORTANCE OF MODELING INTEROCCASION VARIABILITY IN POPULATION PHARMACOKINETIC ANALYSES [J].
KARLSSON, MO ;
SHEINER, LB .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1993, 21 (06) :735-750
[9]   CRITICAL COMPARISON OF NOVEL AND EXISTING METHODS OF COMPLIANCE ASSESSMENT DURING A CLINICAL-TRIAL OF AN ORAL IRON CHELATOR [J].
MATSUI, D ;
HERMANN, C ;
KLEIN, J ;
BERKOVITCH, M ;
OLIVIERI, N ;
KOREN, G .
JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 34 (09) :944-949
[10]   COMPLIANCE ASSESSED BY THE MEDICATION EVENT MONITORING-SYSTEM [J].
OLIVIERI, NF ;
MATSUI, D ;
HERMANN, C ;
KOREN, G .
ARCHIVES OF DISEASE IN CHILDHOOD, 1991, 66 (12) :1399-1402